Vaxfab Enterprises board to consider fund raise via QIP, rights issue

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights
  • Board meeting scheduled for October 1, 2026
  • Agenda includes preferential allotment, rights issue, and QIP
  • Trading window closed from September 25, 2026
  • Fund raising may involve ADRs, GDRs, or FCCBs
powered bylight_fuzz_icon
51882808

*this image is generated using AI for illustrative purposes only.

Vaxfab Enterprises Limited has scheduled a board meeting for Thursday, October 1, 2026, to deliberate on raising funds through various equity and convertible instruments.

The agenda includes augmenting financial resources via preferential allotment, rights issue, qualified institutional placement (QIP), American Depository Receipts (ADR), Global Depository Receipts (GDR), or Fully Convertible Debentures (FCCB). The company stated these options may be executed in one or more tranches.

Trading window closure

In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for designated persons and their immediate relatives closed on September 25, 2026. It will remain closed until 48 hours after the conclusion of the board meeting.

Board meeting details

The meeting will be held at the registered office of the company in Ahmedabad, Gujarat. The primary business item is to consider and approve the issuance of equity shares or other securities to strengthen the balance sheet.

Item Details
Meeting Date October 1, 2026
Venue Registered Office, Ahmedabad
Primary Agenda Fund raising via equity/convertible instruments
Trading Window Closed September 25, 2026

Any other business matters may be transacted with the permission of the Chair. The intimation was filed with BSE Limited and The Calcutta Stock Exchange Limited under Regulation 29 of SEBI (LODR) Regulations, 2015.

Historical Stock Returns for Vaxfab Enterprises

1 Day5 Days1 Month6 Months1 Year5 Years
-0.21%+0.82%-7.91%+54.76%+92.14%+508.61%

How might the chosen capital raising instrument impact existing shareholders' dilution and earnings per share?

What specific growth initiatives or debt repayment plans will the raised funds be allocated to?

How will the company's choice between domestic instruments (QIP/Rights) and global ones (ADR/GDR) affect its international investor base?

Vaxfab Enterprises schedules 43rd AGM for September 29, 2026

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Vaxfab Enterprises posts ₹363.80 lakh PAT for FY26, up from ₹33.72 lakh in FY25
  • Standalone revenue from operations rises 60.4% to ₹9,410.75 lakh
  • Company schedules 43rd AGM for September 29, 2026, with e-voting until September 28
  • Authorized share capital increased to ₹50 crore via equity share expansion
powered bylight_fuzz_icon
50320080

*this image is generated using AI for illustrative purposes only.

Vaxfab Enterprises has scheduled its 43rd Annual General Meeting for Tuesday, September 29, 2026. The company also reported a standalone profit after tax (PAT) of ₹363.80 lakh for FY26, a significant increase from ₹33.72 lakh in the previous year.

The board approved a rise in authorized share capital to ₹50 crore. The meeting will focus on corporate governance updates, including the reappointment of Managing Director Ravindra Ashokbhai Joshi and the appointment of M/s. Chandabhoy & Jassoobhoy as statutory auditors.

Financial Performance

Standalone revenue from operations grew to ₹9,410.75 lakh in FY26, compared to ₹5,867.10 lakh in FY25. Total revenue stood at ₹9,959.59 lakh, driven by other income of ₹548.84 lakh, which rose sharply from ₹70.56 lakh in the prior year.

Metric FY26 FY25 Change
Revenue from Operations ₹9,410.75 lakh ₹5,867.10 lakh +60.4%
Profit Before Tax ₹517.47 lakh ₹45.65 lakh +1,033.6%
Profit After Tax ₹363.80 lakh ₹33.72 lakh +978.6%

Consolidated figures showed a net loss of ₹4,630.84 lakh for FY26, contrasting with a profit of ₹33.72 lakh in FY25. Consolidated revenue from operations was ₹13,126.91 lakh.

Capital Structure Adjustment

The company increased its authorized share capital by ₹15 crore. The revised structure details are as follows:

Share Type Previous Authorized New Authorized Face Value
Equity Shares 3.47 crore units 4.97 crore units ₹10 each
Preference Shares 3 lakh units 3 lakh units ₹10 each
Total Capital ₹35 crore ₹50 crore -

The number of preference shares remains unchanged at 3 lakh units. The entire increase in authorized capital comes from the equity share component, adding 1.5 crore potential equity shares to the company's ceiling.

Annual General Meeting Details

The board scheduled the 43rd annual general meeting for Tuesday, September 29, 2026, at 12:00 pm. The meeting will be held at the registered office in Ahmedabad, Gujarat. The notice was published in Financial Express on September 9, 2026.

Key logistical details include:

  • Remote e-voting facility available from September 26, 2026, at 9:00 am to September 28, 2026, at 5:00 pm.
  • Cut-off date for voting eligibility is September 22, 2026.
  • Mrs. Shubhangi Rajkumar Agarwal appointed as scrutinizer for the venue voting process.

Members holding shares in dematerialized form as on the cut-off date may cast votes through the remote e-voting system or via ballot paper at the AGM.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE560T01015/c5e2be76-574e-4923-80f4-f5830be932e2.pdf

Historical Stock Returns for Vaxfab Enterprises

1 Day5 Days1 Month6 Months1 Year5 Years
-0.21%+0.82%-7.91%+54.76%+92.14%+508.61%

What specific strategic initiatives or business segments are driving the 60% growth in standalone revenue from operations for FY26?

How does the company plan to address the significant divergence between its profitable standalone results and the consolidated net loss of ₹46.3 crore?

Will the increase in authorized share capital to ₹50 crore signal an imminent equity fundraising round or rights issue to fund expansion plans?

More News on Vaxfab Enterprises

1 Year Returns:+92.14%